Aktuellt
SENASTE
Bactiguard’s Q2 report will be the first quarter in which Vigilenz is fully consolidated, and we expect this, together with BIP portfolio sales development to be the main focus for Q2. For H2, we see several triggers, such as the rollout of Hydrocyn in further markets, potential further licence agreements, and new financial targets. Ahead of Q2, we raise our 2020-22 adj. EBITDA estimates by 3-20%, yielding a valuation range of SEK 145-168.
LÄS MER
